Parkman Healthcare Partners LLC Invests $4.86 Million in uniQure (NASDAQ:QURE)

Parkman Healthcare Partners LLC bought a new stake in uniQure (NASDAQ:QURE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 275,000 shares of the biotechnology company's stock, valued at approximately $4,856,000. Parkman Healthcare Partners LLC owned approximately 0.56% of uniQure at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Twin Tree Management LP purchased a new position in shares of uniQure in the 4th quarter valued at about $77,000. FNY Investment Advisers LLC purchased a new position in shares of uniQure during the 4th quarter worth about $88,000. ADAR1 Capital Management LLC purchased a new stake in uniQure during the fourth quarter worth approximately $177,000. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 969 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Trading Down 2.6%

Shares of QURE stock opened at $12.81 on Wednesday. The stock has a market capitalization of $701.68 million, a PE ratio of -2.58 and a beta of 0.10. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The business has a 50-day moving average of $12.25 and a 200 day moving average of $12.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, sell-side analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on QURE. Wells Fargo & Company lowered their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Chardan Capital reaffirmed a "buy" rating and issued a $38.00 target price on shares of uniQure in a research report on Monday. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. Finally, StockNews.com upgraded uniQure to a "sell" rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $37.82.

Insider Activity at uniQure

In related news, CFO Christian Klemt sold 2,916 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at $1,756,501.76. This represents a 1.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares in the company, valued at $6,574,599.40. The trade was a 1.14% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock worth $961,401. Corporate insiders own 4.74% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.